Domů › Metastatický karcinom › Pennsylvania › Pittsburgh
Klinické studie Metastatický karcinom v Pittsburgh, PA
31 studií pro Metastatický karcinom hledá účastníky v lokalitách v Pittsburgh a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Probíhá náborFáze 2
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- a dalších 3
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Probíhá náborFáze 1
- UPMC Hillman Cancer Center, Pittsburgh
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Probíhá náborFáze 2/3
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Probíhá náborFáze 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Probíhá náborFáze 1
- University of Pittsburgh Medical Center, Pittsburgh
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Probíhá náborFáze 3
- AHN Allegheny General Hospital, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Probíhá náborFáze 1/2
- Allegheny Health Network, Pittsburgh
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Probíhá náborFáze 1/2
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- Clinical Study Site, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Probíhá náborFáze 3
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
Probíhá náborFáze 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Probíhá náborFáze 1
- UPMC Hillman Cancer Center, Pittsburgh
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Probíhá náborFáze 1
- Allegheny General Hospital, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Probíhá náborFáze 1
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Probíhá náborFáze 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Probíhá náborFáze 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Probíhá náborFáze 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Probíhá náborFáze 3
- AHN Cancer Center, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Probíhá náborFáze 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Probíhá náborFáze 2/3
- University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center, Pittsburgh
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Probíhá náborFáze 1/2
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Probíhá náborFáze 2/3
- UPMC Hillman Cancer Center, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
Probíhá náborFáze 2
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Probíhá náborFáze 3
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Probíhá náborFáze 2/3
- UPMC Hillman Cancer Center, Pittsburgh
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Probíhá náborFáze 1
- Hillman Cancer Center, Pittsburgh
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
Probíhá náborFáze 2
- Allegheny Health Network West Penn Hospital, Pittsburgh
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Probíhá náborFáze 3
- University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Probíhá náborFáze 1/2
- University of Pittsburgh, Pittsburgh
Studie Metastatický karcinom v jiných městech
- Houston, TX104 studií
- New York City, NY93 studií
- Nashville, TN70 studií
- Boston, MA63 studií
- Los Angeles, CA57 studií
- St. Louis, MO54 studií
- Arlington, VA53 studií
- Philadelphia, PA46 studií
- Chicago, IL45 studií
- San Antonio, TX44 studií
- Washington, DC43 studií
- Dallas, TX42 studií
Další studie v Pittsburgh
- Nemalobuněčný plicní karcinom48 studií
- Rakovina (všechny typy)41 studií
- Rakovina prsu39 studií
- Kolorektální karcinom32 studií
- Melanom31 studií
- Rakovina vaječníků30 studií
- Rakovina endometria23 studií
- Rakovina prostaty23 studií
- Rakovina plic23 studií
- Squamózní buněčný karcinom hlavy a krku22 studií
- Mrtvice22 studií
- Deprese22 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.